FEATURED COMPANIES
- Arena Pharmaceuticals
- Bristol Myers Squibb
- COMPASS pathways
- Eisai Co., Ltd
- Elusis Therapeutics
This “Serotonin receptor 2 Agonist- Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Serotonin receptor 2 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Serotonin receptor 2 Agonist: Overview
Serotonin receptors are Endogenous compounds and drugs that bind to and activate serotonin receptors. Many serotonin receptor agonists are used as antidepressants; anxiolytics; and in the treatment of migraine disorders.
Function - Serotonin 5-HT2A receptors (5-HT2ARs) are widely distributed in the central nervous system, especially in brain region essential for learning and cognition. The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) is a GPCR of the type A family. Within the brain this receptor participates in processes such as cognition and working memory, been implicated in effective disorders such as schizophrenia, and mediate the primary effects of hallucinogenic drugs. In the periphery, receptors have been linked to vasoconstriction and hypertension, and to inflammatory processes that can lead to atherosclerosis.
Serotonin receptor 2 Agonist- Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity.
Serotonin receptor 2 Agonist Emerging Drugs Chapters
This segment of the Serotonin receptor 2 Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Serotonin receptor 2 Agonist Emerging Drugs
Aripiprazole: Bristol Myers Squibb
Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors. Dopamine and serotonin are natural compounds called neurotransmitters, and are involved in transmitting messages between brain cells. The drug is being evaluated in phase III for the treatment of Pervasive child development disorders and agitation.
Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. The therapy is under investigation in phase II stage of development for the treatment of patients with bipolar depression and other depressive disorders.
Serotonin receptor 2 Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Serotonin receptor 2 Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Serotonin receptor 2 Agonist
There are approx. 5+ key companies which are developing the Serotonin receptor 2 Agonist. The companies which have their Serotonin receptor 2 Agonist drug candidates in the most advanced stage, i.e. preregistration include, Bristol Myers Squibb.
Phases
This report covers around 5+ products under different phases of clinical development like
Serotonin receptor 2 Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin receptor 2 Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin receptor 2 Agonist drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin receptor 2 Agonist R&D. The therapies under development are focused on novel approaches for Serotonin receptor 2 Agonist.
Serotonin receptor 2 Agonist Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Serotonin receptor 2 Agonist: Overview
Serotonin receptors are Endogenous compounds and drugs that bind to and activate serotonin receptors. Many serotonin receptor agonists are used as antidepressants; anxiolytics; and in the treatment of migraine disorders.
Function - Serotonin 5-HT2A receptors (5-HT2ARs) are widely distributed in the central nervous system, especially in brain region essential for learning and cognition. The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) is a GPCR of the type A family. Within the brain this receptor participates in processes such as cognition and working memory, been implicated in effective disorders such as schizophrenia, and mediate the primary effects of hallucinogenic drugs. In the periphery, receptors have been linked to vasoconstriction and hypertension, and to inflammatory processes that can lead to atherosclerosis.
Serotonin receptor 2 Agonist- Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity.
Serotonin receptor 2 Agonist Emerging Drugs Chapters
This segment of the Serotonin receptor 2 Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Serotonin receptor 2 Agonist Emerging Drugs
Aripiprazole: Bristol Myers Squibb
Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors. Dopamine and serotonin are natural compounds called neurotransmitters, and are involved in transmitting messages between brain cells. The drug is being evaluated in phase III for the treatment of Pervasive child development disorders and agitation.
Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. The therapy is under investigation in phase II stage of development for the treatment of patients with bipolar depression and other depressive disorders.
Serotonin receptor 2 Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Serotonin receptor 2 Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Serotonin receptor 2 Agonist
There are approx. 5+ key companies which are developing the Serotonin receptor 2 Agonist. The companies which have their Serotonin receptor 2 Agonist drug candidates in the most advanced stage, i.e. preregistration include, Bristol Myers Squibb.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Serotonin receptor 2 Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin receptor 2 Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin receptor 2 Agonist drugs.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin receptor 2 Agonist R&D. The therapies under development are focused on novel approaches for Serotonin receptor 2 Agonist.
Serotonin receptor 2 Agonist Report Insights
- Serotonin receptor 2 Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Serotonin receptor 2 Agonist drugs?
- How many Serotonin receptor 2 Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Serotonin receptor 2 Agonist?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Serotonin receptor 2 Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Serotonin receptor 2 Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Arena Pharmaceuticals
- Bristol Myers Squibb
- COMPASS pathways
- Eisai Co., Ltd
- Elusis Therapeutics
Introduction
Executive Summary
Serotonin receptor 2 Agonist: Overview
In-depth Commercial Assessment
Serotonin receptor 2 Agonist Key Products
Serotonin receptor 2 Agonist- Unmet Needs
Serotonin receptor 2 Agonist- Market Drivers and Barriers
Serotonin receptor 2 Agonist- Future Perspectives and Conclusion
Serotonin receptor 2 Agonist Analyst Views
Serotonin receptor 2 Agonist Key Companies
Appendix
List of Tables
Table 1 Total Products for Serotonin receptor 2 Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Serotonin receptor 2 Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Serotonin receptor 2 Agonist: Overview
- Structure
- Mechanism of Action
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Serotonin receptor 2 Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Serotonin receptor 2 Agonist Key Products
Serotonin receptor 2 Agonist- Unmet Needs
Serotonin receptor 2 Agonist- Market Drivers and Barriers
Serotonin receptor 2 Agonist- Future Perspectives and Conclusion
Serotonin receptor 2 Agonist Analyst Views
Serotonin receptor 2 Agonist Key Companies
Appendix
List of Tables
Table 1 Total Products for Serotonin receptor 2 Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Serotonin receptor 2 Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
- Bristol Myers Squibb
- Elusis Therapeutics
- Eisai Co., Ltd
- COMPASS pathways
- Arena Pharmaceuticals
Note: Product cover images may vary from those shown
